Prediagnosis aspirin use and outcomes in a prospective cohort of esophageal cancer patients

Conclusions:
In our cohort of esophageal cancer patients, prediagnosis aspirin use was not associated with all-cause or cancer-specific mortality. However, risk of interval metastatic disease was increased among those who took aspirin regularly prediagnosis. Future studies are warranted to assess whether aspirin influences the molecular characteristics of esophageal tumors, with potential prognostic and therapeutic implications.

Source: Therapeutic Advances in Gastroenterology - October 20, 2016 Category: Gastroenterology Authors: Araujo, J. L., Altorki, N. K., Sonett, J. R., Rodriguez, A., Sungur-Stasik, K., Spinelli, C. F., Neugut, A. I., Abrams, J. A. Tags: Original Research Source Type: research